| Name | Title | Contact Details |
|---|
Gulf Coast Center is a Galveston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Princeton Biomedical Laboratories is a White Oak, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mercy and Truth Medical Missions is a non-profit organization that provides healthcare to the underserved people of the Kansas City community and world through Christian service.
Neptune Wellness is a publicly-held modern, (plant forward) CPG company driven by a singular purpose: to transform the everyday for a healthier tomorrow. Building upon our 20+ years of expertise in nutraceutical manufacturing and cannabis extraction, as well as a superior seed to shelf supply chain, we`re developing a suite of good-for-you, good-for-the-planet consumer brands across multiple verticals – including nutraceuticals, cannabis, personal care & beauty, food & beverage, and home. This transition to a fully integrated consumer packaged goods company enables Neptune to forge a new path in consumer health and wellness, with industry-changing implications.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.